Montvida O, et al. - In this study, researchers assessed the risk of acute pancreatitis, pancreatic cancer, and other pancreatic diseases following second-line anti-hyperglycemic agent initiation in individuals with metformin-treated diabetes. Using the US Centricity Electronic Medical Records, they identified individuals with type 2 diabetes diagnosed after 2004 who received metformin in combination with a dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, sulfonylurea, thiazolidinedione, or insulin for ≥ 3 months. They did not find significant differences in the risk of developing pancreatic diseases in those treated with various anti-hyperglycemic drug classes.